汇宇制药(688553.SH)：依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准

Core Viewpoint - The company, Huyou Pharmaceutical (688553.SH), has received approval from the U.S. FDA for its new drug applications (NDA) for Etoposide Injection and Fluorouracil Injection, allowing it to produce and sell these products in the U.S. market [1] Group 1: Product Approvals - Etoposide Injection is a topoisomerase inhibitor used in combination with other chemotherapy and/or immunotherapy treatments for adult patients with refractory testicular cancer and small cell lung cancer [1] - Fluorouracil Injection is indicated for the treatment of colon cancer, rectal cancer, breast cancer, gastric adenocarcinoma, and pancreatic cancer [1] Group 2: Market Expansion - The FDA approval signifies the company's eligibility to sell products in the U.S. market, which will help expand its sales in the U.S., strengthen its product supply chain, and enrich its product portfolio [1] - This development lays a solid foundation for the sustainable growth of the company in international markets [1]